These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 23791150)

  • 1. Proteomic analysis of rat tibialis anterior muscles at different stages of experimental autoimmune myasthenia gravis.
    Gomez AM; Vanheel A; Losen M; Molenaar PC; De Baets MH; Noben JP; Hellings N; Martinez-Martinez P
    J Neuroimmunol; 2013 Aug; 261(1-2):141-5. PubMed ID: 23791150
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased expression of rapsyn in muscles prevents acetylcholine receptor loss in experimental autoimmune myasthenia gravis.
    Losen M; Stassen MH; Martínez-Martínez P; Machiels BM; Duimel H; Frederik P; Veldman H; Wokke JH; Spaans F; Vincent A; De Baets MH
    Brain; 2005 Oct; 128(Pt 10):2327-37. PubMed ID: 16150851
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overexpression of rapsyn in rat muscle increases acetylcholine receptor levels in chronic experimental autoimmune myasthenia gravis.
    Martínez-Martínez P; Losen M; Duimel H; Frederik P; Spaans F; Molenaar P; Vincent A; De Baets MH
    Am J Pathol; 2007 Feb; 170(2):644-57. PubMed ID: 17255332
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RNA expression analysis of passive transfer myasthenia supports extraocular muscle as a unique immunological environment.
    Zhou Y; Kaminski HJ; Gong B; Cheng G; Feuerman JM; Kusner L
    Invest Ophthalmol Vis Sci; 2014 Jun; 55(7):4348-59. PubMed ID: 24917137
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changes in acetylcholinesterase in experimental autoimmune myasthenia gravis and in response to treatment with a specific antisense.
    Blotnick E; Hamra-Amitai Y; Wald C; Brenner T; Anglister L
    Eur J Neurosci; 2012 Oct; 36(8):3077-85. PubMed ID: 22805122
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role for interferon-gamma in rat strains with different susceptibility to experimental autoimmune myasthenia gravis.
    Wang HB; Shi FD; Li H; van der Meide PH; Ljunggren HG; Link H
    Clin Immunol; 2000 May; 95(2):156-62. PubMed ID: 10779409
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Myocyte production of nitric oxide in response to AChR-reactive antibodies in two inbred rat strains may influence disease outcome in experimental myasthenia gravis.
    Garcia YR; Pothitakis JC; Krolick KA
    Clin Immunol; 2003 Feb; 106(2):116-26. PubMed ID: 12672402
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Muscle-specific regulation of the mTOR signaling pathway in MuSK antibody seropositive (MuSK+) experimental autoimmune Myasthenia gravis (EAMG).
    Chauhan M; Punga T; Punga AR
    Neurosci Res; 2013; 77(1-2):102-9. PubMed ID: 23933211
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Experimental autoimmune myasthenia gravis in the mouse.
    Wu B; Goluszko E; Huda R; Tüzün E; Christadoss P
    Curr Protoc Immunol; 2013; Chapter 15():Unit 15.8.. PubMed ID: 23392639
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ATRA alters humoral responses associated with amelioration of EAMG symptoms by balancing Tfh/Tfr helper cell profiles.
    Xie X; Mu L; Yao X; Li N; Sun B; Li Y; Zhan X; Wang X; Kang X; Wang J; Liu Y; Zhang Y; Wang G; Wang D; Liu X; Kong Q; Li H
    Clin Immunol; 2013 Aug; 148(2):162-76. PubMed ID: 23773919
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Decreased bone mineral density in experimental myasthenia gravis in C57BL/6 mice.
    Oshima M; Iida-Klein A; Maruta T; Deitiker PR; Atassi MZ
    Autoimmunity; 2017 Sep; 50(6):346-353. PubMed ID: 28850269
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of passively transferred experimental autoimmune myasthenia gravis using papain.
    Poulas K; Tsouloufis T; Tzartos SJ
    Clin Exp Immunol; 2000 May; 120(2):363-8. PubMed ID: 10792389
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Muscle satellite cells are functionally impaired in myasthenia gravis: consequences on muscle regeneration.
    Attia M; Maurer M; Robinet M; Le Grand F; Fadel E; Le Panse R; Butler-Browne G; Berrih-Aknin S
    Acta Neuropathol; 2017 Dec; 134(6):869-888. PubMed ID: 28756524
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of Grilled Nux Vomica on Differential RNA Expression Profile of Gastrocnemius Muscle and Toll‑Like Receptor 4 (TLR-4)/Nuclear Factor kappa B (NF-κB) Signaling in Experimental Autoimmune Myasthenia Gravis Rats.
    Jiang XH; Chen Y; Ding YY; Qiu H; Zhou DY; Qiu CL
    Med Sci Monit; 2020 Feb; 26():e919150. PubMed ID: 32052794
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunosuppression of experimental autoimmune myasthenia gravis by mycophenolate mofetil.
    Janssen SP; Phernambucq M; Martinez-Martinez P; De Baets MH; Losen M
    J Neuroimmunol; 2008 Sep; 201-202():111-20. PubMed ID: 18667242
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The limitation of IL-10-exposed dendritic cells in the treatment of experimental autoimmune myasthenia gravis and myasthenia gravis.
    Xiao BG; Duan RS; Zhu WH; Lu CZ
    Cell Immunol; 2006 Jun; 241(2):95-101. PubMed ID: 17005165
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acetylcholine receptor-induced experimental myasthenia gravis: what have we learned from animal models after three decades?
    Baggi F; Antozzi C; Toscani C; Cordiglieri C
    Arch Immunol Ther Exp (Warsz); 2012 Feb; 60(1):19-30. PubMed ID: 22159475
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The thymus in myasthenia gravis. Changes typical for the human disease are absent in experimental autoimmune myasthenia gravis of the Lewis rat.
    Meinl E; Klinkert WE; Wekerle H
    Am J Pathol; 1991 Nov; 139(5):995-1008. PubMed ID: 1951638
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Engineered agrin attenuates the severity of experimental autoimmune myasthenia gravis.
    Li Z; Li M; Wood K; Hettwer S; Muley SA; Shi FD; Liu Q; Ladha SS
    Muscle Nerve; 2018 May; 57(5):814-820. PubMed ID: 29193204
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Suppression of experimental autoimmune myasthenia gravis by combination therapy: pentoxifylline as a steroid-sparing agent.
    Menon RT; Feferman T; Aricha R; Souroujon MC; Fuchs S
    J Neuroimmunol; 2008 Sep; 201-202():128-35. PubMed ID: 18632163
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.